References
- Weiss RA. How does HIV cause AIDS? Science 1993;260:1273–1279.
- Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol 2010;13:524–529.
- Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425–1431.
- Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981;305:1431–1438.
- Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–871.
- Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA 1991;88:1339–1343.
- Hagmann M. Study confirms effectiveness of antiretroviral drugs for HIV patients. Bull World Health Organ 2003;81:918–919.
- Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001;276:23213–23216.
- d’Angelo J, Mouscadet JF, Desmaële D, Zouhiri F, Leh H. HIV-1 integrase: the next target for AIDS therapy? Pathol Biol 2001;49:237–246.
- Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010;65:2485–2488.
- Goodarzi G, Im GJ, Brackmann K, Grandgenett D. Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase. J Virol 1995;69:6090–6097.
- Chow SA, Vincent KA, Ellison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992;255:723–726.
- Kukolj G, Skalka AM. Enhanced and coordinated processing of synapsed viral DNA ends by retroviral integrases in vitro. Genes Dev 1995;9:2556–2567.
- Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999;96:13040–13043.
- Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992;66:6361–6369.
- Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994;266:1981–1986.
- Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 1997;4:567–577.
- Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647–671.
- Dixon SL, Smondyrev AM, Rao SN. PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 2006;67:370–372.
- Phase 3.2, User manual. Schrödinger, New York, NY, 2010.
- Phase, version 3.2. Schrödinger, New York, NY, 2010.
- Gardelli C, Nizi E, Muraglia E, Crescenzi B, Ferrara M, Orvieto F et al. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. J Med Chem 2007;50:4953–4975.
- Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008;51:5843–5855.
- Halgren TA. MMFF VI: MMFF94s option for energy minimization studies. J Comp Chem, 1999;20:720–729.
- Evans DA, Doman TN, Thorner DA, Bodkin MJ. 3D QSAR methods: Phase and Catalyst compared. J Chem Inf Model 2007;47:1248–1257.
- Narkhede S, Degani M. Pharmacophore refinement and 3D-QSAR studies of histamine H3 antagonists. QSAR Combinatorial Sci 2007;26:744–753.
- Tawari NR, Bag S, Degani MS. Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. J Mol Model 2008;14:911–921.
- Li Y, Wang Y, Zhang F. Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors. J Mol Model 2010;16:1449–1460.
- Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inf 2010;29:476–488.